uniQure (NASDAQ:QURE) Price Target Raised to $65.00 at Wells Fargo & Company

uniQure (NASDAQ:QURE) had its price target raised by Wells Fargo & Company from $30.00 to $65.00 in a report published on Thursday, MarketBeat reports. The firm currently has an overweight rating on the biotechnology company’s stock.

QURE has been the topic of several other research reports. Leerink Partners upped their price objective on uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research report on Wednesday. Chardan Capital upped their price objective on uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price objective on the stock in a research report on Thursday, August 14th. Cantor Fitzgerald upped their price objective on uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $64.64.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $52.65 on Thursday. uniQure has a twelve month low of $4.45 and a twelve month high of $54.98. The company’s 50 day moving average is $16.65 and its 200 day moving average is $14.61. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $2.89 billion, a PE ratio of -13.43 and a beta of 0.14.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. On average, sell-side analysts forecast that uniQure will post -3.75 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Main Management ETF Advisors LLC lifted its position in shares of uniQure by 1.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 912 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of uniQure during the 2nd quarter valued at approximately $117,000. Birchview Capital LP lifted its position in shares of uniQure by 11.3% during the 2nd quarter. Birchview Capital LP now owns 98,697 shares of the biotechnology company’s stock valued at $1,376,000 after buying an additional 10,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in uniQure by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock valued at $2,968,000 after purchasing an additional 10,019 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.